Amgen beats analysts’ expectations for earnings and revenue in Q2
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen to buy ChemoCentryx for $3.7B
Amgen was having a relatively quiet year on the mergers and acquisitions front, at least until Aug. 4, when the Thousand Oaks-based biotech firm announced it will purchase ChemoCentryx for nearly $3.7 billion. ChemoCentryx is a Silicon Valley biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It has Read More →
Arcutis to raise $150M in public stock offering
Arcutis Biotherapeutics, a Westlake Village-based company developing drugs for immune dermatological conditions, plans to raise $150 million through a public offering of additional shares of common stock. Arcutis announced the pricing of those shares on Aug. 2, at $20 per share. Shares of Arcutis closed at $19.50 that day and then shot up 17% on Read More →
Cure sells $20M in intellectual property, replaces CEO and CFO
Oxnard-based Cure Pharmaceutical, a drug delivery platform and CBD products company, will be selling a portion of its intellectual property and related assets for $20 million, the company announced July 28. The buyer was a company called TF Tech Ventures, and the deal closed July 22, Cure said in a July 28 filing with the Read More →
Community Health Centers honored for safety net and pandemic programs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Oma Fertility raises $37.5M in quest to revolutionize IVF treatment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Sientra wins new FDA approval
The U.S. Food and Drug Administration approved a new breast implant on July 6 made by Goleta-based Sientra. Sientra’s Low Plus Profile Projection Breast Implant will be commercially available to plastic surgeons in the United States in late July, the company said in a news release. It is for cosmetic surgery for women at least Read More →
